Consensus MediciNova, Inc.

Equities

MNOV

US58468P2065

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
1.42 ^USD	-0.70%		-7.19%	-5.33%

May. 14	MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome	CI
May. 09	MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on MediciNova, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f680dbefc1e6b9e00b3.ckKFmH1cW1vFzgcLY-OtREy1hOeHOxmwZLU_sG6NqOs.FSbDrisECmKa_URRKoHBDhri_N7TTVTIMtB0wyXvn40TAf-vDgQVCJCYNw~725e64e9db108f81db1b32aa9ae9123e

Analyst Recommendations on MediciNova, Inc.

MediciNova Says Alcohol-Use Disorder Drug Reduced Rates of Heavy Drinking, Alcohol Craving in Mid-Stage Trial	22-04-08	MT
Maxim Group Adjusts MediciNova Price Target to $6 From $10, Maintains Buy Rating	22-02-02	MT
B. Riley Lowers MediciNova's Price Target to $6 from $11 After Revising Cost Capital Assumptions, Keeps Buy Rating	22-01-24	MT
MEDICINOVA : Maxim Starts MediciNova at Buy With $15 Price Target	21-03-10	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.42 USD

Average target price

17 USD

Spread / Average Target

+1,097.18%

High Price Target

28 USD

Spread / Highest target

+1,871.83%

Low Price Target

6 USD

Spread / Lowest Target

+322.54%

Consensus detail

Consensus revision (last 18 months)

Analysts covering MediciNova, Inc.

Maxim
B. Riley

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar